Impact of SARS-CoV-2 infection on tuberculosis outcome and follow-up in Italy during the first COVID-19 pandemic wave: a nationwide online survey.

Q2 Medicine

Infezioni in Medicina Pub Date : 2022-09-01 eCollection Date: 2022-01-01 DOI:10.53854/liim-3003-10

Diana Canetti, Roberta Maria Antonello, Laura Saderi, Mara Giro, Delia Goletti, Loredana Sarmati, Paola Rodari, Marialuisa Bocchino, Miriam Schirò, Niccolò Riccardi, Giovanni Sotgiu

{"title":"Impact of SARS-CoV-2 infection on tuberculosis outcome and follow-up in Italy during the first COVID-19 pandemic wave: a nationwide online survey.","authors":"Diana Canetti, Roberta Maria Antonello, Laura Saderi, Mara Giro, Delia Goletti, Loredana Sarmati, Paola Rodari, Marialuisa Bocchino, Miriam Schirò, Niccolò Riccardi, Giovanni Sotgiu","doi":"10.53854/liim-3003-10","DOIUrl":null,"url":null,"abstract":"Background: SARS-CoV-2 pandemic affected tuberculosis (TB) management. This Italian nationwide survey assessed COVID-19 impact on TB care and outcomes.Materials and methods: Twenty-one hospitals or referral centres fulfilled an online survey. Primary objective was to describe clinical features, outcomes and retention in care in subjects with latent TB infection (LTBI) or disease over the first wave of COVID-19 pandemic. Secondary objectives were the assessment of risk factors, co-morbidities, diagnostics, radiological findings, and outcomes of COVID-19 in the study population.Results: 254 patients with LTBI or active TB were included. In co-infected (SARS-CoV-2, LTBI/TB) patients, recovery occurred in 29/32 (90.6%) cases, death in one case. High retention in care was preserved.Conclusion: in our cohort, outcomes did not seem to be adversely conditioned by incident COVID-19.","PeriodicalId":52423,"journal":{"name":"Infezioni in Medicina","volume":"30 3","pages":"418-426"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448321/pdf/1124-9390_30_3_2022_418-426.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infezioni in Medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53854/liim-3003-10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: SARS-CoV-2 pandemic affected tuberculosis (TB) management. This Italian nationwide survey assessed COVID-19 impact on TB care and outcomes.

Materials and methods: Twenty-one hospitals or referral centres fulfilled an online survey. Primary objective was to describe clinical features, outcomes and retention in care in subjects with latent TB infection (LTBI) or disease over the first wave of COVID-19 pandemic. Secondary objectives were the assessment of risk factors, co-morbidities, diagnostics, radiological findings, and outcomes of COVID-19 in the study population.

Results: 254 patients with LTBI or active TB were included. In co-infected (SARS-CoV-2, LTBI/TB) patients, recovery occurred in 29/32 (90.6%) cases, death in one case. High retention in care was preserved.

Conclusion: in our cohort, outcomes did not seem to be adversely conditioned by incident COVID-19.

查看原文本刊更多论文

在 COVID-19 第一次大流行期间，SARS-CoV-2 感染对意大利结核病治疗结果和随访的影响：一项全国性在线调查。

背景：SARS-CoV-2大流行影响了结核病（TB）管理。这项意大利全国性调查评估了 COVID-19 对结核病治疗和结果的影响：21 家医院或转诊中心参与了在线调查。首要目标是描述 COVID-19 大流行第一波期间潜伏肺结核感染（LTBI）或疾病患者的临床特征、治疗效果和保留率。次要目标是评估研究人群中 COVID-19 的风险因素、并发症、诊断、放射学结果和治疗效果。在合并感染（SARS-CoV-2、LTBI/肺结核）的患者中，29/32（90.6%）例痊愈，1例死亡。结论：在我们的队列中，COVID-19事件似乎不会对治疗结果产生不利影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infezioni in Medicina Medicine-Infectious Diseases

CiteScore

8.40

自引率

0.00%

发文量

期刊介绍： The Journal publishes original papers, in Italian or in English, on topics concerning aetiopathogenesis, prevention, epidemiology, diagnosis, clinical features and therapy of infections, whose acceptance is subject to the referee’s assessment. The Journal is of interest not only to infectious disease specialists, microbiologists and pharmacologists, but also to internal medicine specialists, paediatricians, pneumologists, and to surgeons as well. The Editorial Board includes experts in each of the above mentioned fields.